United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
| Revenue (TTM) | $3.19B |
| Gross Profit (TTM) | $2.75B |
| EBITDA | $1.35B |
| Operating Margin | 29.00% |
| Return on Equity | 19.10% |
| Return on Assets | 10.90% |
| Revenue/Share (TTM) | $74.08 |
| Book Value | $148.08 |
| Price-to-Book | 3.84 |
| Price-to-Sales (TTM) | 7.51 |
| EV/Revenue | 6.58 |
| EV/EBITDA | 12.98 |
| Quarterly Earnings Growth (YoY) | -20.30% |
| Quarterly Revenue Growth (YoY) | 4.10% |
| Shares Outstanding | $42.59M |
| Float | $38.94M |
| % Insiders | 2.02% |
| % Institutions | 100.53% |
Volatility is currently contracting
United Therapeutics NASDAQ: UTHR reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission for its soft mist inhaler to 2027.
United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $7.16 per share a year ago.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025. “United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. The company celebrated the openi.
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on UTHR and any ticker you trade — then tracks every position and per-strategy win rate.
